Satellos Bioscience (TSE:MSCL) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Satellos Bioscience has initiated a Phase 1 clinical trial with the first participant dosed with SAT-3247, a new drug aimed at regenerating muscle in Duchenne muscular dystrophy and other muscle-related conditions. The company expects to collect initial data on safety and pharmacokinetics by Q4 2024 and plans to start trials with DMD patients in early 2025. This marks a significant advancement for Satellos, positioning them as a clinical stage company.
For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.